about
Serum FABP5 concentration is a potential biomarker for residual risk of atherosclerosis in relation to cholesterol efflux from macrophagesElevation of circulating fatty acid-binding protein 4 is independently associated with left ventricular diastolic dysfunction in a general population.Emerging issues in radiogenic cataracts and cardiovascular diseaseReduction of endoplasmic reticulum stress inhibits neointima formation after vascular injury.Fatty Acid-Binding Protein 4 (FABP4): Pathophysiological Insights and Potent Clinical Biomarker of Metabolic and Cardiovascular Diseases.Transcriptome and Metabolome Analyses in Exogenous FABP4- and FABP5-Treated Adipose-Derived Stem CellsReduction of circulating FABP4 level by treatment with omega-3 fatty acid ethyl esters.Local Production of Fatty Acid-Binding Protein 4 in Epicardial/Perivascular Fat and Macrophages Is Linked to Coronary Atherosclerosis.Impact of use of angiotensin II receptor blocker on all-cause mortality in hemodialysis patients: prospective cohort study using a propensity-score analysis.Independent Link Between Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and FABP4 in a General Population Without Medication.Ectopic Fatty Acid-Binding Protein 4 Expression in the Vascular Endothelium is Involved in Neointima Formation After Vascular Injury.Angiotensin II receptor blockers decrease serum concentration of fatty acid-binding protein 4 in patients with hypertension.Impact of the Number of Anti-Thrombosis Agents in Hemodialysis Patients: BOREAS-HD2 Study.Accuracy of flush glucose monitoring in insulin-treated patients with type 2 diabetesIndependent links between plasma xanthine oxidoreductase activity and levels of adipokinesReply to the comment of Hirota et al. on "Accuracy of flash glucose monitoring in insulin-treated patients with type 2 diabetes"Differential regulation of hypoxanthine and xanthine by obesity in a general populationLow urine pH predicts new onset of diabetes mellitus during a 10-year period in male subjects: BOREAS-DM1 StudyPotential differential effects of renin-angiotensin system inhibitors on SARS-CoV-2 infection and lung injury in COVID-19
P50
Q33669547-FA4E3C7A-D0EF-4DF7-A09A-2895FBF56725Q34103605-A0EE91EB-A03D-464A-808B-9AF882D4ACBAQ34366572-54990BD7-AF8A-44AA-A8BA-40545C424286Q34460553-3727DC5D-BFCB-4911-99F0-9CA7C8E4A655Q35042217-C8103048-B4C5-4AA4-B109-DAFA59FC7DBAQ36218431-9291BC02-5E49-4CDC-A574-4E6649DE62CDQ36454709-5FDAB282-0D34-4357-BC88-6D7641335844Q38783204-5F78D946-9F00-4ABF-9A31-2628402AF187Q40394425-1E39C9FB-FFD4-4948-8826-716FF13A09EAQ40727953-D9C6F13D-7EE6-4987-86E1-1518E033051EQ42373725-E2175AED-0F55-4501-8572-F20C118F4762Q42830503-39919CE8-DC2A-458F-90D0-B922A974CB45Q47966987-0AA08E27-7D6E-46B1-91F2-351F63A21100Q57280889-8CA43757-A855-47BF-9483-EB3754E545B6Q90269927-D7988A46-E2DD-4A6F-8D35-3024BA019B49Q91320736-B98A54C1-3983-4CB2-A0BE-CC03A155A325Q92509912-CBB50D8B-CDB3-4B8A-9525-2EF32FDDC681Q94463273-588CE81F-19C1-4BF0-9B03-4F7F314C9242Q95321983-B271CC92-6940-4ED5-B949-E3A3C473338D
P50
description
researcher (ORCID 0000-0002-0145-3541)
@en
name
Masato Furuhashi
@en
type
label
Masato Furuhashi
@en
prefLabel
Masato Furuhashi
@en
P31
P496
0000-0002-0145-3541